Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James P Thomas

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Case Reports in Endocrinology|January 24, 2014
Chemotherapy-induced regression of an adrenocorticotropin-secreting pituitary carcinoma accompanied by secondary adrenal insufficiencyRobert Frank Cornell, Daniel F Kelly, Gal Bordo, et al.
European Journal of Cancer (Oxford, England : 1990)|April 29, 2014
Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic diseaseMichael Hwang, Thejus T Jayakrishnan, Danielle E Green, et al.
International Journal of Radiation Oncology, Biology, Physics|April 24, 2007
Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortiumAndrew Kennedy, Subir Nag, Riad Salem, et al.
Cancer Chemotherapy and Pharmacology|February 4, 2010
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumorsBrian S Choi, Dona B Alberti, William R Schelman, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2002
Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridolJames P Thomas, Kendra D Tutsch, James F Cleary, et al.
Investigational New Drugs|November 27, 2002
Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancySherry Morgan-Meadows, James P Thomas, Daniel Mulkerin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumorsJames P Thomas, Rhoda Z Arzoomanian, Dona Alberti, et al.
Journal of Inorganic Biochemistry|December 7, 2007
Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with TriapineJill M Kolesar, William R Schelman, Peter G Geiger, et al.
Clinical Advances in Hematology & Oncology : H&O|March 7, 2008
Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinomaSteven Attia, Kyle D Holen, James P Thomas, et al.
Experimental and Therapeutic Medicine|March 5, 2011
Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic ResonanceJill M Kolesar, Kamakshi Sachidanandam, William R Schelman, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Case Reports in Endocrinology|January 24, 2014
Chemotherapy-induced regression of an adrenocorticotropin-secreting pituitary carcinoma accompanied by secondary adrenal insufficiencyRobert Frank Cornell, Daniel F Kelly, Gal Bordo, et al.
European Journal of Cancer (Oxford, England : 1990)|April 29, 2014
Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic diseaseMichael Hwang, Thejus T Jayakrishnan, Danielle E Green, et al.
International Journal of Radiation Oncology, Biology, Physics|April 24, 2007
Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortiumAndrew Kennedy, Subir Nag, Riad Salem, et al.
Cancer Chemotherapy and Pharmacology|February 4, 2010
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumorsBrian S Choi, Dona B Alberti, William R Schelman, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2002
Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridolJames P Thomas, Kendra D Tutsch, James F Cleary, et al.
Investigational New Drugs|November 27, 2002
Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancySherry Morgan-Meadows, James P Thomas, Daniel Mulkerin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumorsJames P Thomas, Rhoda Z Arzoomanian, Dona Alberti, et al.
Journal of Inorganic Biochemistry|December 7, 2007
Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with TriapineJill M Kolesar, William R Schelman, Peter G Geiger, et al.
Clinical Advances in Hematology & Oncology : H&O|March 7, 2008
Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinomaSteven Attia, Kyle D Holen, James P Thomas, et al.
Experimental and Therapeutic Medicine|March 5, 2011
Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic ResonanceJill M Kolesar, Kamakshi Sachidanandam, William R Schelman, et al.
Pageof 5